Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Cyclophosphamide 216Methotrexate 140Cytarabine 131Vincristine 110fludarabine phosphate 103Peripheral Blood Stem Cell Transplantation 97Filgrastim 92Etoposide 91Dexamethasone 89Mycophenolic Acid 70Doxorubicin 70Whole-Body Irradiation 66Mercaptopurine 66Tacrolimus 64Busulfan 64Radiotherapy 63Cyclosporine 61Prednisone 55Daunorubicin 53pegaspargase 51Asparaginase 51Rituximab 48fludarabine 47Granulocyte Colony-Stimulating Factor 46Melphalan 45Antilymphocyte Serum 43Clofarabine 42Calcium Dobesilate 38Methylprednisolone 36Leucovorin 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tablets × Clear all
NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Nova Laboratories Limited

Phase 1 Completed
70 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡